Literature DB >> 22128285

c-MET as a potential therapeutic target and biomarker in cancer.

J Rafael Sierra1, Ming-Sound Tsao.   

Abstract

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.

Entities:  

Keywords:  c-MET; cancer; hepatocyte growth factor; personalized medicine; targeted therapy

Year:  2011        PMID： 22128285      PMCID： PMC3225018          DOI： 10.1177/1758834011422557

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  160 in total

1.  Different point mutations in the met oncogene elicit distinct biological properties.

Authors:  S Giordano; A Maffe; T A Williams; S Artigiani; P Gual; A Bardelli; C Basilico; P Michieli; P M Comoglio
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

2.  MET receptor sequence variants R970C and T992I lack transforming capacity.

Authors:  Jeffrey W Tyner; Luke B Fletcher; Ellen Q Wang; Wayne F Yang; Michael L Rutenberg-Schoenberg; Carol Beadling; Motomi Mori; Michael C Heinrich; Michael W Deininger; Brian J Druker; Marc M Loriaux
Journal:  Cancer Res       Date:  2010-08-01       Impact factor: 12.701

3.  Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

Authors:  M Olivero; G Valente; A Bardelli; P Longati; N Ferrero; C Cracco; C Terrone; S Rocca-Rossetti; P M Comoglio; M F Di Renzo
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

Review 4.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

5.  Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met.

Authors:  Laurel Stevens; Lindy McClelland; Alex Fricke; Magali Williamson; Ihsin Kuo; Glynis Scott
Journal:  J Invest Dermatol       Date:  2010-02-18       Impact factor: 8.551

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Authors:  Michael S Gordon; Christopher S Sweeney; David S Mendelson; S Gail Eckhardt; Abraham Anderson; Darrin M Beaupre; Daniel Branstetter; Teresa L Burgess; Angela Coxon; Hongjie Deng; Paula Kaplan-Lefko; Ian M Leitch; Kelly S Oliner; Lucy Yan; Min Zhu; Lia Gore
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

8.  Sema4D induces angiogenesis through Met recruitment by Plexin B1.

Authors:  Paolo Conrotto; Donatella Valdembri; Simona Corso; Guido Serini; Luca Tamagnone; Paolo Maria Comoglio; Federico Bussolino; Silvia Giordano
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

9.  Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

Authors:  E Ichimura; A Maeshima; T Nakajima; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1996-10

10.  Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells.

Authors:  G M Argast; C H Croy; K L Couts; Z Zhang; E Litman; D C Chan; N G Ahn
Journal:  Oncogene       Date:  2009-06-01       Impact factor: 9.867
View more
  141 in total

1.  Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Authors:  Yohei Funakoshi; Toru Mukohara; Hideo Tomioka; Roudy Chiminch Ekyalongo; Yu Kataoka; Yumiko Inui; Yuriko Kawamori; Masanori Toyoda; Naomi Kiyota; Yutaka Fujiwara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2013-04-09       Impact factor: 3.850

Review 2.  Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Authors:  Giovanna Finocchiaro; Luca Toschi; Letizia Gianoncelli; Marina Baretti; Armando Santoro
Journal:  Ann Transl Med       Date:  2015-04

Review 3.  Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Authors:  Raffaele Califano; Floriana Morgillo; Ramon Andrade De Mello; Giannis Mountzios
Journal:  Ann Transl Med       Date:  2015-04

Review 4.  Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

5.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

6.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

7.  Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.

Authors:  Yilong Zhang; Mita Kuchimanchi; Min Zhu; Sameer Doshi; Tien Hoang; Sreeneeranj Kasichayanula
Journal:  Br J Clin Pharmacol       Date:  2016-12-13       Impact factor: 4.335

8.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

9.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 10.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.